{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:12:19Z","timestamp":1785247939046,"version":"3.55.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,18]]},"DOI":"10.7759\/cureus.86322","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T05:31:29Z","timestamp":1750311089000},"source":"Crossref","is-referenced-by-count":1,"title":["Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Myeloid Leukemias"],"prefix":"10.7759","author":[{"given":"Yazeed","family":"Alekrish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafar","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamer","family":"Aleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang N","year":"2023","unstructured":"Zhang N, Wu J, Wang Q, et al.. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023, 13:82. 10.1038\/s41408-023-00853-3","journal-title":"Blood Cancer J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang X","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012, 118:3123-7. 10.1002\/cncr.26679","journal-title":"Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00649-y","article-title":"Global, regional, and national burden of acute myeloid leukemia, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"12","author":"Zhou Y","year":"2024","unstructured":"Zhou Y, Huang G, Cai X, Liu Y, Qian B, Li D. Global, regional, and national burden of acute myeloid leukemia, 1990-2021: a systematic analysis for the global burden of disease study 2021. Biomark Res. 2024, 12:101. 10.1186\/s40364-024-00649-y","journal-title":"Biomark Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1369246","article-title":"Exploring treatment decision-making in chronic myeloid leukemia in chronic phase","volume":"14","author":"Andorsky D","year":"2024","unstructured":"Andorsky D, Kota V, Sweet K. Exploring treatment decision-making in chronic myeloid leukemia in chronic phase. Front Oncol. 2024, 14:1369246. 10.3389\/fonc.2024.1369246","journal-title":"Front Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023 - common ground and common sense","volume":"13","author":"Senapati J","year":"2023","unstructured":"Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 2023, 13:58. 10.1038\/s41408-023-00823-9","journal-title":"Blood Cancer J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143429","article-title":"Targeting tyrosine kinases in acute myeloid leukemia: why, who and how?","volume":"20","author":"Fernandez S","year":"2019","unstructured":"Fernandez S, Desplat V, Villacreces A, et al.. Targeting tyrosine kinases in acute myeloid leukemia: why, who and how?. Int J Mol Sci. 2019, 20:3429. 10.3390\/ijms20143429","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100675","article-title":"Tyrosine kinase inhibitors for acute myeloid leukemia: a step toward disease control?","volume":"44","author":"Meg\u00edas-Vericat JE","year":"2020","unstructured":"Meg\u00edas-Vericat JE, Ballesta-L\u00f3pez O, Barrag\u00e1n E, Mart\u00ednez-Cuadr\u00f3n D, Montesinos P. Tyrosine kinase inhibitors for acute myeloid leukemia: a step toward disease control?. Blood Rev. 2020, 44:100675. 10.1016\/j.blre.2020.100675","journal-title":"Blood Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139264","article-title":"Safety and efficacy of tyrosine kinase inhibitors in acute myeloid leukemia: a systematic review and meta-analysis of randomized clinical trials","volume":"136","author":"Fatima FN","year":"2020","unstructured":"Fatima FN, Anwer F, Ali MA, et al.. Safety and efficacy of tyrosine kinase inhibitors in acute myeloid leukemia: a systematic review and meta-analysis of randomized clinical trials. Blood. 2020, 136:18. 10.1182\/blood-2020-139264","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(93)81308-M","article-title":"Effects of tyrosine-kinase inhibitors on protein-kinase-independent systems","volume":"316","author":"Young SW","year":"1993","unstructured":"Young SW, Poole RC, Hudson AT, et al.. Effects of tyrosine-kinase inhibitors on protein-kinase-independent systems. FEBS Lett. 1993, 316:278-82. 10.1016\/0014-5793(93)81308-M","journal-title":"FEBS Lett"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez V","year":"2019","unstructured":"Garc\u00eda-Guti\u00e9rrez V, Hern\u00e1ndez-Boluda JC. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol. 2019, 9:603. 10.3389\/fonc.2019.00603","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10120503","article-title":"Transporter and lysosomal mediated (Multi)drug resistance to tyrosine Kinase inhibitors and potential strategies to overcome Resistance","volume":"10","author":"de Klerk DJ","year":"2018","unstructured":"de Klerk DJ, Honeywell RJ, Jansen G, Peters GJ. Transporter and lysosomal mediated (Multi)drug resistance to tyrosine Kinase inhibitors and potential strategies to overcome Resistance. Cancers (Basel). 2018, 10:503. 10.3390\/cancers10120503","journal-title":"Cancers (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien SG","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, et al.. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003, 348:994-1004. 10.1056\/NEJMoa022457","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13045","article-title":"Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level","volume":"93","author":"Brenner H","year":"2008","unstructured":"Brenner H, Gondos A, Pulte D. Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica. 2008, 93:1544-9. 10.3324\/haematol.13045","journal-title":"Haematologica"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower H","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016, 34:2851-7. 10.1200\/JCO.2015.66.2866","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11629","article-title":"Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"98","author":"Cortes J","year":"2003","unstructured":"Cortes J, Talpaz M, O'Brien S, et al.. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003, 98:1105-13. 10.1002\/cncr.11629","journal-title":"Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.03.018","article-title":"Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia","volume":"123","author":"Wiggins CL","year":"2010","unstructured":"Wiggins CL, Harlan LC, Nelson HE, Stevens JL, Willman CL, Libby EN, Hromas RA. Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. Am J Med. 2010, 123:764.e1-9. 10.1016\/j.amjmed.2010.03.018","journal-title":"Am J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-020-01540-1","article-title":"FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research-a systematic review and meta-analysis","volume":"9","author":"Majothi S","year":"2020","unstructured":"Majothi S, Adams D, Loke J, Stevens SP, Wheatley K, Wilson JS. FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research-a systematic review and meta-analysis. Syst Rev. 2020, 9:285. 10.1186\/s13643-020-01540-1","journal-title":"Syst Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone RM","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, et al.. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017, 377:454-64. 10.1056\/NEJMoa1614359","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed FLT3-ITD-positive AML (QuANTUM-First)","volume":"401","author":"Erba HP","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, et al.. Quizartinib plus chemotherapy in newly diagnosed FLT3-ITD-positive AML (QuANTUM-First). Lancet. 2023, 401:1571-83. 10.1016\/S0140-6736(23)00464-6","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao JC","year":"2022","unstructured":"Zhao JC, Agarwal S, Ahmad H, Amin K, Bewersdorf JP, Zeidan AM. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 2022, 52:100905. 10.1016\/j.blre.2021.100905","journal-title":"Blood Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21873","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian HM","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, et al.. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin. 2025, 75:46-67. 10.3322\/caac.21873","journal-title":"CA Cancer J Clin"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl AE","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, et al.. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019, 381:1728-40. 10.1056\/NEJMoa1902688","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML","volume":"42","author":"Short NJ","year":"2024","unstructured":"Short NJ, Daver N, Dinardo CD, et al.. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol. 2024, 42:1499-508. 10.1200\/JCO.23.01911","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to STI571 in leukemic cells through gene amplification","volume":"95","author":"Le Coutre P","year":"2000","unstructured":"Le Coutre P, Tassi E, Varella-Garcia M, et al.. Induction of resistance to STI571 in leukemic cells through gene amplification. Blood. 2000, 95:1758-66. 10.1182\/blood.V95.5.1758.005a41_1758_1766","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Quint\u00e1s-Cardama A","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009, 16:122-31. 10.1177\/107327480901600204","journal-title":"Cancer Control"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.03.018","article-title":"Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options","volume":"13","author":"Jabbour EJ","year":"2013","unstructured":"Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013, 13:515-29. 10.1016\/j.clml.2013.03.018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre ME","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001, 293:876-80. 10.1126\/science.1062538","journal-title":"Science"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus A","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS, et al.. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002, 16:2190-6. 10.1038\/sj.leu.2402741","journal-title":"Leukemia"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini S","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, et al.. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011, 118:1208-15. 10.1182\/blood-2010-12-326405","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"M\u00fcller MC","year":"2009","unstructured":"M\u00fcller MC, Cortes JE, Kim DW, et al.. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009, 114:4944-53. 10.1182\/blood-2009-04-214221","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes T","year":"2009","unstructured":"Hughes T, Saglio G, Branford S, et al.. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009, 27:4204-10. 10.1200\/JCO.2009.21.8230","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2012.10.028","article-title":"Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors","volume":"141","author":"Marc\u00e9 S","year":"2013","unstructured":"Marc\u00e9 S, Zamora L, Cabez\u00f3n M, et al.. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. Med Clin (Barc). 2013, 141:95-9. 10.1016\/j.medcli.2012.10.028","journal-title":"Med Clin (Barc)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL mutations confer polyclonal resistance to imatinib","volume":"2","author":"Shah NP","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, et al.. Multiple BCR-ABL mutations confer polyclonal resistance to imatinib. Cancer Cell. 2002, 2:117-25. 10.1016\/S1535-6108(02)00096-X","journal-title":"Cancer Cell"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1473573","article-title":"Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors","volume":"60","author":"Erbilgin Y","year":"2019","unstructured":"Erbilgin Y, Eskazan AE, Hatirnaz Ng O, et al.. Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors. Leuk Lymphoma. 2019, 60:200-7. 10.1080\/10428194.2018.1473573","journal-title":"Leuk Lymphoma"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00058","article-title":"Spectrum of BCR-ABL mutations and treatment outcomes in ethiopian imatinib-resistant patients with chronic myeloid leukemia","author":"Tadesse F","year":"2021","unstructured":"Tadesse F, Asres G, Abubeker A, Gebremedhin A, Radich J. Spectrum of BCR-ABL mutations and treatment outcomes in ethiopian imatinib-resistant patients with chronic myeloid leukemia. JCO Glob Oncol. 2021, 1187-93. 10.1200\/GO.21.00058","journal-title":"JCO Glob Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun TP","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020, 37:530-42. 10.1016\/j.ccell.2020.03.006","journal-title":"Cancer Cell"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus A","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, et al.. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020, 34:966-84. 10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0993","article-title":"Functional consequence of MDR1 expression on imatinib intracellular concentrations","volume":"102","author":"Widmer N","year":"2003","unstructured":"Widmer N, Colombo S, Buclin T, Decosterd LA. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood. 2003, 102:1142. 10.1182\/blood-2003-03-0993","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1126\/science.1168750","article-title":"Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding","volume":"323","author":"Aller SG","year":"2009","unstructured":"Aller SG, Yu J, Ward A, et al.. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009, 323:1718-22. 10.1126\/science.1168750","journal-title":"Science"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.045260","article-title":"Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux","volume":"304","author":"Dai H","year":"2003","unstructured":"Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther. 2003, 304:1085-92. 10.1124\/jpet.102.045260","journal-title":"J Pharmacol Exp Ther"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.011.10327","article-title":"Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells","volume":"31","author":"Peng XX","year":"2012","unstructured":"Peng XX, Tiwari AK, Wu HC, Chen ZS. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells. Chin J Cancer. 2012, 31:110-8. 10.5732\/cjc.011.10327","journal-title":"Chin J Cancer"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23374","article-title":"Overexpression of P-glycoprotein and resistance to Imatinib in chronic myeloid leukemia patients","volume":"34","author":"Ammar M","year":"2020","unstructured":"Ammar M, Louati N, Frikha I, et al.. Overexpression of P-glycoprotein and resistance to Imatinib in chronic myeloid leukemia patients. J Clin Lab Anal. 2020, 34:e23374. 10.1002\/jcla.23374","journal-title":"J Clin Lab Anal"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1172\/JCI127080","article-title":"SIRT1 regulates metabolism and leukemogenic potential in CML stem cells","volume":"129","author":"Abraham A","year":"2019","unstructured":"Abraham A, Qiu S, Chacko BK, et al.. SIRT1 regulates metabolism and leukemogenic potential in CML stem cells. J Clin Invest. 2019, 129:2685-701. 10.1172\/JCI127080","journal-title":"J Clin Invest"},{"key":"ref44","article-title":"Combined JAK\/STAT5A and BCR-ABL inhibition impairs blast-crisis CML stem cell self-renewal","volume":"120","author":"Recart ACC","year":"2012","unstructured":"Recart ACC, Goff DJ, Sadarangani A, et al.. Combined JAK\/STAT5A and BCR-ABL inhibition impairs blast-crisis CML stem cell self-renewal. Blood. 2012, 120:910.","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton A","year":"2012","unstructured":"Hamilton A, Helgason GV, Schemionek M, et al.. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012, 119:1501-10. 10.1182\/blood-2010-12-326843","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/129715","article-title":"HOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients","volume":"2013","author":"Elias MH","year":"2013","unstructured":"Elias MH, Baba AA, Husin A, et al.. HOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients. Biomed Res Int. 2013, 2013:129715. 10.1155\/2013\/129715","journal-title":"Biomed Res Int"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022110","article-title":"Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia","volume":"6","author":"Jelinek J","year":"2011","unstructured":"Jelinek J, Gharibyan V, Estecio MR, et al.. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One. 2011, 6:e22110. 10.1371\/journal.pone.0022110","journal-title":"PLoS One"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00532","article-title":"The Wnt pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia","volume":"9","author":"Grassi S","year":"2019","unstructured":"Grassi S, Palumbo S, Mariotti V, et al.. The Wnt pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia. Front Oncol. 2019, 9:532. 10.3389\/fonc.2019.00532","journal-title":"Front Oncol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.191","article-title":"Mutations of FLT3\/ITD confer resistance to multiple tyrosine kinase inhibitors","volume":"27","author":"Williams AB","year":"2013","unstructured":"Williams AB, Nguyen B, Li L, Brown P, Levis M, Leahy D, Small D. Mutations of FLT3\/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia. 2013, 27:48-55. 10.1038\/leu.2012.191","journal-title":"Leukemia"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed\/refractory FLT3-ITD AML (QuANTUM-R)","volume":"20","author":"Cortes JE","year":"2019","unstructured":"Cortes JE, Khaled S, Martinelli G, et al.. Quizartinib versus salvage chemotherapy in relapsed\/refractory FLT3-ITD AML (QuANTUM-R). Lancet Oncol. 2019, 20:984-97. 10.1016\/S1470-2045(19)30150-0","journal-title":"Lancet Oncol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015826","article-title":"FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia","volume":"110","author":"Mead AJ","year":"2007","unstructured":"Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood. 2007, 110:1262-70. 10.1182\/blood-2006-04-015826","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner H","year":"2010","unstructured":"D\u00f6hner H, Estey EH, Amadori S, et al.. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010, 115:453-74. 10.1182\/blood-2009-07-235358","journal-title":"Blood"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1653","article-title":"Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells","volume":"103","author":"Bagrintseva K","year":"2004","unstructured":"Bagrintseva K, Schwab R, Kohl TM, et al.. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Blood. 2004, 103:2266-75. 10.1182\/blood-2003-05-1653","journal-title":"Blood"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007626","article-title":"Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin","volume":"137","author":"Schmalbrock LK","year":"2021","unstructured":"Schmalbrock LK, Dolnik A, Cocciardi S, et al.. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021, 137:3093-104. 10.1182\/blood.2020007626","journal-title":"Blood"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145762","article-title":"The FLT3 F691L gatekeeper mutation promotes clinical resistance to Gilteritinib+ Venetoclax (GILT+ VEN) in AML","volume":"138","author":"Sharzehi S","year":"2021","unstructured":"Sharzehi S, Joshi SK, Pittsenbarger J, Tyner JW, Traer E. The FLT3 F691L gatekeeper mutation promotes clinical resistance to Gilteritinib+ Venetoclax (GILT+ VEN) in AML. Blood. 2021, 138:2235. 10.1182\/blood-2021-145762","journal-title":"Blood"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711820","article-title":"Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis","volume":"130","author":"Smith CC","year":"2017","unstructured":"Smith CC, Paguirigan A, Jeschke GR, et al.. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood. 2017, 130:48-58. 10.1182\/blood-2016-04-711820","journal-title":"Blood"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2469","article-title":"Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain","volume":"107","author":"Heidel F","year":"2006","unstructured":"Heidel F, Solem FK, Breitenbuecher F, et al.. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood. 2006, 107:293-300. 10.1182\/blood-2005-06-2469","journal-title":"Blood"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08263-x","article-title":"Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms","volume":"10","author":"Zhang H","year":"2019","unstructured":"Zhang H, Savage S, Schultz AR, et al.. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun. 2019, 10:244. 10.1038\/s41467-018-08263-x","journal-title":"Nat Commun"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00687-5","article-title":"Resistance to targeted therapies: delving into FLT3 and IDH","volume":"12","author":"Desikan SP","year":"2022","unstructured":"Desikan SP, Daver N, DiNardo C, Kadia T, Konopleva M, Ravandi F. Resistance to targeted therapies: delving into FLT3 and IDH. Blood Cancer J. 2022, 12:91. 10.1038\/s41408-022-00687-5","journal-title":"Blood Cancer J"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0143","article-title":"Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors","volume":"2","author":"Alotaibi AS","year":"2021","unstructured":"Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, et al.. Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors. Blood Cancer Discov. 2021, 2:125-34. 10.1158\/2643-3230.BCD-20-0143","journal-title":"Blood Cancer Discov"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon CM","year":"2019","unstructured":"McMahon CM, Ferng T, Canaani J, et al.. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019, 9:1050-63. 10.1158\/2159-8290.CD-18-1453","journal-title":"Cancer Discov"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-266742","article-title":"FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo","volume":"117","author":"Sato T","year":"2011","unstructured":"Sato T, Yang X, Knapper S, et al.. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood. 2011, 117:3286-93. 10.1182\/blood-2010-01-266742","journal-title":"Blood"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10147","article-title":"Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells","volume":"7","author":"Chen F","year":"2016","unstructured":"Chen F, Ishikawa Y, Akashi A, Naoe T, Kiyoi H. Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Oncotarget. 2016, 7:47018-32. 10.18632\/oncotarget.10147","journal-title":"Oncotarget"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding L","year":"2012","unstructured":"Ding L, Ley TJ, Larson DE, et al.. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012, 481:506-10. 10.1038\/nature10738","journal-title":"Nature"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12599","article-title":"Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase","volume":"164","author":"Yang X","year":"2014","unstructured":"Yang X, Sexauer A, Levis M. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. Br J Haematol. 2014, 164:61-72. 10.1111\/bjh.12599","journal-title":"Br J Haematol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005702","article-title":"Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics","volume":"108","author":"DeAngelo DJ","year":"2006","unstructured":"DeAngelo DJ, Stone RM, Heaney ML, et al.. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006, 108:3674-81. 10.1182\/blood-2006-02-005702","journal-title":"Blood"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05545-3","article-title":"Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia","volume":"103","author":"Lap CJ","year":"2024","unstructured":"Lap CJ, Abrahim MS, Nassereddine S. Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia. Ann Hematol. 2024, 103:2215-29. 10.1007\/s00277-023-05545-3","journal-title":"Ann Hematol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3614","article-title":"Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes","volume":"6","author":"Alonso S","year":"2015","unstructured":"Alonso S, Su M, Jones JW, Ganguly S, Kane MA, Jones RJ, Ghiaur G. Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes. Oncotarget. 2015, 6:14905-12. 10.18632\/oncotarget.3614","journal-title":"Oncotarget"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018022921","article-title":"Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3\/ITD AML from tyrosine kinase inhibitors","volume":"3","author":"Chang YT","year":"2019","unstructured":"Chang YT, Hernandez D, Alonso S, et al.. Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3\/ITD AML from tyrosine kinase inhibitors. Blood Adv. 2019, 3:908-16. 10.1182\/bloodadvances.2018022921","journal-title":"Blood Adv"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-3569","article-title":"FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"76","author":"Traer E","year":"2016","unstructured":"Traer E, Martinez J, Javidi-Sharifi N, et al.. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia. Cancer Res. 2016, 76:6471-82. 10.1158\/0008-5472.CAN-15-3569","journal-title":"Cancer Res"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143300","article-title":"FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"14","author":"Poudel G","year":"2022","unstructured":"Poudel G, Tolland MG, Hughes TP, Pagani IS. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia. Cancers (Basel). 2022, 14:3300. 10.3390\/cancers14143300","journal-title":"Cancers (Basel)"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115875","article-title":"Mitochondrial complex I inhibition by homoharringtonine: a novel strategy for suppression of chronic myeloid leukemia","volume":"218","author":"Han H","year":"2023","unstructured":"Han H, Zhao C, Liu M, et al.. Mitochondrial complex I inhibition by homoharringtonine: a novel strategy for suppression of chronic myeloid leukemia. Biochem Pharmacol. 2023, 218:115875. 10.1016\/j.bcp.2023.115875","journal-title":"Biochem Pharmacol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.6.1029","article-title":"Homoharringtonine for the treatment of chronic myelogenous leukemia","volume":"9","author":"Quint\u00e1s-Cardama A","year":"2008","unstructured":"Quint\u00e1s-Cardama A, Cortes J. Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert Opin Pharmacother. 2008, 9:1029-37. 10.1517\/14656566.9.6.1029","journal-title":"Expert Opin Pharmacother"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.821464","article-title":"Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia","volume":"14","author":"Nazha A","year":"2013","unstructured":"Nazha A, Kantarjian H, Cortes J, Quint\u00e1s-Cardama A. Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia. Expert Opin Pharmacother. 2013, 14:1977-86. 10.1517\/14656566.2013.821464","journal-title":"Expert Opin Pharmacother"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0842-9","article-title":"Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors","volume":"34","author":"Hochhaus A","year":"2020","unstructured":"Hochhaus A, Breccia M, Saglio G, Garc\u00eda-Guti\u00e9rrez V, R\u00e9a D, Janssen J, Apperley J. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020, 34:1495-502. 10.1038\/s41375-020-0842-9","journal-title":"Leukemia"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi JJ","year":"2015","unstructured":"Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015, 33:4210-8. 10.1200\/JCO.2015.62.4718","journal-title":"J Clin Oncol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes TP","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, et al.. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019, 381:2315-26. 10.1056\/NEJMoa1902328","journal-title":"N Engl J Med"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26764","article-title":"Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT","volume":"98","author":"Chalandon Y","year":"2023","unstructured":"Chalandon Y, Sbianchi G, Gras L, et al.. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT. Am J Hematol. 2023, 98:112-21. 10.1002\/ajh.26764","journal-title":"Am J Hematol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000329","article-title":"Transplantation in CML in the TKI era: who, when, and how?","volume":"2022","author":"Niederwieser C","year":"2022","unstructured":"Niederwieser C, Kr\u00f6ger N. Transplantation in CML in the TKI era: who, when, and how?. Hematology Am Soc Hematol Educ Program. 2022, 2022:114-22. 10.1182\/hematology.2022000329","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00964-5","article-title":"Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML","volume":"13","author":"Yilmaz M","year":"2020","unstructured":"Yilmaz M, Alfayez M, DiNardo CD, et al.. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2020, 13:132. 10.1186\/s13045-020-00964-5","journal-title":"J Hematol Oncol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246181","article-title":"Efficacy and synergy of small molecule inhibitors targeting FLT3-ITD(+) acute myeloid leukemia","volume":"13","author":"Bregante J","year":"2021","unstructured":"Bregante J, Sch\u00f6nbichler A, P\u00f6l\u00f6ske D, et al.. Efficacy and synergy of small molecule inhibitors targeting FLT3-ITD(+) acute myeloid leukemia. Cancers. 2021, 13:618. 10.3390\/cancers13246181","journal-title":"Cancers"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247346","article-title":"A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia","volume":"106","author":"Lee L","year":"2021","unstructured":"Lee L, Hizukuri Y, Severson P, et al.. A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia. Haematologica. 2021, 106:1022-33. 10.3324\/haematol.2020.247346","journal-title":"Haematologica"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112992","article-title":"Modulation of FLT3-ITD localization and targeting of distinct downstream signaling pathways as potential strategies to overcome FLT3-inhibitor resistance","volume":"10","author":"Fleischmann M","year":"2021","unstructured":"Fleischmann M, Fischer M, Schnetzke U, et al.. Modulation of FLT3-ITD localization and targeting of distinct downstream signaling pathways as potential strategies to overcome FLT3-inhibitor resistance. Cells. 2021, 10:2992. 10.3390\/cells10112992","journal-title":"Cells"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0858-1","article-title":"Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms","volume":"34","author":"Patel AB","year":"2020","unstructured":"Patel AB, Pomicter AD, Yan D, et al.. Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia. 2020, 34:2981-91. 10.1038\/s41375-020-0858-1","journal-title":"Leukemia"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0060","article-title":"Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 \"gatekeeper\" F691l mutation with PLX3397","volume":"5","author":"Smith CC","year":"2015","unstructured":"Smith CC, Zhang C, Lin KC, et al.. Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 \"gatekeeper\" F691l mutation with PLX3397. Cancer Discov. 2015, 5:668-79. 10.1158\/2159-8290.CD-15-0060","journal-title":"Cancer Discov"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-786657","article-title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations","volume":"131","author":"Yamaura T","year":"2018","unstructured":"Yamaura T, Nakatani T, Uda K, et al.. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. Blood. 2018, 131:426-38. 10.1182\/blood-2017-05-786657","journal-title":"Blood"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01196","article-title":"Discovery of a potent FLT3 inhibitor (LT-850-166) with the capacity of overcoming a variety of FLT3 mutations","volume":"64","author":"Wang Z","year":"2021","unstructured":"Wang Z, Cai J, Ren J, et al.. Discovery of a potent FLT3 inhibitor (LT-850-166) with the capacity of overcoming a variety of FLT3 mutations. J Med Chem. 2021, 64:14664-701. 10.1021\/acs.jmedchem.1c01196","journal-title":"J Med Chem"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI127907","article-title":"Targeting AML-associated FLT3 mutations with a type I kinase inhibitor","volume":"130","author":"Jones LM","year":"2020","unstructured":"Jones LM, Melgar K, Bolanos L, et al.. Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. J Clin Invest. 2020, 130:2017-23. 10.1172\/JCI127907","journal-title":"J Clin Invest"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/379035-mechanisms-of-resistance-to-tyrosine-kinase-inhibitors-in-myeloid-leukemias","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T05:31:29Z","timestamp":1750311089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/379035-mechanisms-of-resistance-to-tyrosine-kinase-inhibitors-in-myeloid-leukemias"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":88,"URL":"https:\/\/doi.org\/10.7759\/cureus.86322","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,18]]}}}